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The role of GSK-3 in oncogenesis is paradoxical, acting as a tumor suppressor in some cancers and poten-
tiating growth in others. In this issue ofCancer Cell, Wang et al. provide somemechanistic insight into GSK-3
activity’s role in potentiating leukemias which are dependent on homeobox (HOX) gene misregulation.Glycogen synthase kinase-3 (GSK-3) was
first identified for its role in regulating
glycogen metabolism but has since been
shown to be involved in the regulation
of a variety of processes including signal
transduction, gene expression, and cell-
fate determination (Jope and Johnson,
2004). These critical roles have become
increasingly more appreciated as misre-
gulated GSK-3 has been implicated in
neurological disorders (i.e., Alzheimer’s
disease and bipolar disorder), non-
insulin-dependent diabetes mellitus,
stroke, and neoplasias (Cohen andFrame,
2001; Rayasam et al., 2009). With over
40 proteins identified as potential GSK-3
substrates, it is not surprising that a
complicated network of GSK-3 func-
tioning has emerged (Jope and Johnson,
2004). This complexity is particularly
evident in cancer where GSK-3 can take
on seemingly opposing roles in tumor
suppression or promotion (Ougolkov and
Billadeau, 2006; Luo, 2009).
Decreased expression or activity of
GSK-3 has been associated with skin
and breast tumors. In vitro and in vivo
rescue experiments in which active
GSK-3 is restored to transformed tumor-
cells leads to suppression of cell prolifer-
ation. Tumor-suppressive functioning ofGSK-3 has been shown to involve the
WNT signaling pathway in which active
GSK-3 negatively regulates b-catenin
through inhibitory phosphorylation and
prevents transcription of b-catenin target
genes involved in cell-cycle progression
(Figure 1). Decreased expression or
activity of GSK-3 could, then, activate
theWNT signaling pathway through stabi-
lization of b-catenin and contribute to
tumorigenesis (Luo, 2009; Rayasam
et al., 2009). In contrast, overexpression
of active GSK-3 is associated with
increased proliferation and decreased
patient survival of some cancers through
pathways which are thought to involve cy-
clin D1 and NF-kB (Luo, 2009).
This opposing function of GSK-3 as
a tumor promoter has also been sug-
gested for acute leukemia in a report by
Wang and colleagues in which MLL-asso-
ciated leukemia was shown to depend on
GSK-3 for sustained proliferation of trans-
formed cells (Wang et al., 2008). Pharma-
cologic inhibition of GSK-3 caused
decreased proliferation, reduced cell-
cycle progression, and increased myeloid
differentiation of leukemia cells that had
been transformed with chimeric MLL on-
coproteins. Decreased GSK-3 activity in
MLL leukemia cells was associated withincreased levels of b-catenin, decreased
cell proliferation in vitro, and enhanced
survival of mice with these leukemias
in vivo. An increase in the CDK inhibitor,
p27Kip1, expression was observed specif-
ically in MLL leukemia cells upon treat-
ment with GSK-3 inhibitors suggesting
that GSK-3 may override cell-cycle regu-
lators in MLL cells to enhance prolifera-
tion, though the exact mechanism re-
mained unclear.
In the current issue of Cancer Cell,
Wang et al. present a follow-up of their
previous study where they begin to delin-
eate the mechanism whereby MLL leuke-
mias depend on GSK-3 for maintenance
of proliferation and transformation (Wang
et al., 2010). Their data demonstrate that
GSK-3 activity promotes the formation
of a HOX/MEIS1/CREB complex that
recruits coactivators CBP and TORC to
maintain the MLL leukemia stem cell tran-
scription program. It has been well estab-
lished that homeobox (HOX) genes
become misregulated in aggressive
leukemias involving MLL translocations
(Shah and Sukumar, 2010). During normal
hematopoiesis, MLL maintains appro-
priate HOX gene expression in hemato-
poietic stem and progenitor cells. As
progenitor cells mature into differentiated17, June 15, 2010 ª2010 Elsevier Inc. 529
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Figure 1. The Seemingly Contrary Roles of GSK-3 Help to Maintain a Fine Balance between
Normal Cell-Cycle Progression and Tumorigenesis
Constitutively active GSK-3 acts to destabilize b-catenin through phosphorylation, thus, functioning as
a tumor suppressor to limit proliferation (unshaded region). In contrast, GSK-3 promotes expansion of
leukemic cells transformed by HOX overexpression through phosphorylation of CREB and subsequent
formation of a transcriptional coactivator complex (shaded region).
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Previewscells of a committed lineage, the expres-
sion of HOX cluster genes become down-
regulated. MLL fusion proteins, on the
other hand, cause the aberrant expres-
sion of target HOX transcription factors
that function in concert with MEIS1 to
maintain a transformed capacity in
leukemia cells. Wang and colleagues
now show that GSK-3 functions down-
stream of MLL fusion proteins to facilitate
HOX-mediated transcription (Figure 1).
Pharmacologic inhibition of GSK-3 in
HOX-transformed cells (or functional inhi-
bition via conditional expression of AKT)
shows decreased proliferation and
decreased HOX/MEIS1 transcriptional
activity. This inhibitor sensitivity is depen-
dent on the presence of CREB, which is
shown to recruit coactivators CBP and
TORC to activate transcription of HOX/
MEIS1 target genes. The association of
this transcriptional activating complex,530 Cancer Cell 17, June 15, 2010 ª2010 Elsdependent on GSK-3 serine/threonine
kinase activity, ultimately allows for the
maintenance of a transformation program
which promotes proliferation of the
leukemia stem cells.
The identification of a functional role for
GSK-3 in MLL-associated leukemia
suggests that GSK-3 inhibitors may be
a promising therapy that is selective for
transformed cells that are dependent on
HOX overexpression. It has also been re-
ported that 90% of AML cases have aber-
rant expression of caudal-type homeobox
transcription factor (CDX2), another regu-
lator of HOX genes, further suggesting
that proper HOX functioning is critical for
maintaining a balance between normal
and pathologic states (Rice and Licht,
2007). GSK-3 inhibitors might prove to be
particularly efficacious in these CDX2-
overexpressing leukemias and those with
MLL translocations that exhibit HOX mis-evier Inc.regulation. In vivo preclinical studies of
GSK-3 inhibitionwith lithiumchloride have
already shown promise in prolonging
survival of mice with HOX-transformed
leukemias (Wang et al., 2008, 2010). The
lithium ion, though, is a relatively nonspe-
cific inhibitor that competes with magne-
sium for protein binding, so off-target
effects are likely to occur as may also
be the case with GSK-3 inhibitors which
competitively inhibit ATP binding. Now
that a critical complex has been identified
as a target for GSK-3 activity in MLL
leukemias, more specific substrate inhib-
itors may be developed that selectively
target the critical formation of the HOX/
MEIS1/CREB complex. It is also possible
that monotherapy with a GSK-3 inhibitor
may deplete normal hematopoietic stem
cells (HSCs) in addition to targeting
leukemic stem cells dependent on GSK-
3 activity. A recent report has shown that
GSK-3 is necessary for self-renewal of
normal HSCs and that knockdown of
both a and b GSK-3 isoforms may signifi-
cantly deplete these normal HSC pools
(Huang et al., 2009). Combination therapy
with rapamycin may maintain the HSC
pool while allowing the GSK-3 inhibitor
to deplete the leukemia stem cells for an
effective therapy against this aggressive
form of leukemia.
It will be important to understand how
the tumor-promoting function of GSK-3
is counterbalanced by its tumor sup-
pressor functions in leukemic cells,
particularly if GSK-3 inhibitors are used
therapeutically, which may ultimately
block activity in either capacity. Cells
that are dependent on the tumor sup-
pressor actions of GSK-3 could be
adversely affected by GSK-3 inhibition.
What factors ultimately determine which
function of GSK-3 function will predomi-
nate in a cell? Can the opposing activities
of GSK-3 be utilized to override the HOX-
mediated oncogenic program proposed
by Wang et al.? A better appreciation of
GSK-3 functions in signal transduction,
cell-cycle regulation, and cell-fate deter-
mination may eventually allow for the
effective application of GSK-3 inhibitors
in the clinic. Wang et al. provide a novel
mechanism by which GSK-3 promotes
transformation, and in doing so, the
authors provide a new therapeutic
strategy which may lead to better clinical
outcomes for aggressive MLL-associated
leukemias.
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MLL1 fusions are among the most potent oncogenic drivers of leukemia development. In recent articles pub-
lished inMolecular Cell and in Cancer Cell, researchers find that MLL1 fusions are reliant on a physical inter-
action with the PAF transcription elongation complex for their recruitment to chromatin and, consequently,
leukemic transformation.Acute myeloid or lymphoid leukemias
harboring rearrangements of the MLL1
gene represent a poor-prognosis subset
of these diseases with a general unre-
sponsiveness to chemotherapy (reviewed
in Krivtsov and Armstrong, 2007). Chro-
mosomal translocations that disrupt
MLL1 generate oncogenic gene fusions
encoding the MLL1 N-terminal region
fused tooneof a variety of different partner
proteins (>50 are known). A consistent
feature of otherwise diverse fusion part-
ners is the corruption of MLL1’s normal
capacity to promote self-renewal of
hematopoietic cells. The resulting MLL1
fusion undermines normal differentiation
pathways to immortalize hematopoietic
cells in an immature state. While evidence
frommousemodelshasestablishedMLL1
fusions as among the most potent drivers
of leukemia known, effective strategies
have yet to be identified for neutralizing
leukemic MLL1 functions for therapeutic
benefit. One avenue toward identifying
novel therapeutic handles in theseaggres-
sive leukemias is to elucidate the essential
biochemical framework of MLL1 fusionprotein complexes. Two recent articles
published in Cancer Cell and Molecular
Cell have made a pivotal advance in this
regard by identifying a specific interaction
between the PAF complex and MLL1 that
is required for leukemic transformation
(Milne et al., 2010; Muntean et al., 2010).
Hence, PAF is exposed as a conspirator
that, along with two other MLL1-associ-
ated proteins, Menin and LEDGF,
promotes leukemogenesis conferred by
MLL1 fusion proteins.
MLL1 performs its normal and leukemic
functions through involvement with active
chromatin states (Krivtsov andArmstrong,
2007). Like many other chromatin regula-
tors, MLL1 is composed of an assortment
of domains (AT hooks, CXXC, BROMO,
PHD) that can latch onto DNA or histones,
as well as a catalytic SET domain at the
C terminus that methylates histone H3
at lysine 4, a modification implicated in
active transcription (Milne et al., 2002).
MLL1also hasbeen shown to interactwith
numerous proteins to form a higher-order
complex, e.g., Menin, LEDGF, HCF-1,
ASH2L, RbBP5, and WDR5 (Yokoyamaet al., 2004). In contrast to the full-length
molecule, the MLL1 fragment present in
leukemogenic fusions only retains the
Menin/LEDGF interaction domain, AT
hooks, and the CXXC domain, which
together are sufficient for recruitment to
target sites in the genome. Distortion of
MLL1 function is due to the replacement
of its native C-terminal effector domains
with those provided by one of many
C-terminal fusion partners. Indeed, a large
number of studies have identified protein
complexes associated with many of the
most commonMLL1 fusion partners (ENL,
AF4, and AF9), all of which seem to share
a group of factors linked with regulating
transcription elongation, e.g., pTEFb and
the histone methyltransferase DOT1L
(e.g., Mueller et al., 2007). Thus, MLL1
fusions assemble a multisubunit complex
of transcriptional regulators that leads
to altered expression of MLL1’s normal
target genes, such as HOXA9.
A major mechanistic question ad-
dressed in the articles by Muntean et al.
(2010) and Milne et al. (2010) regards the
recruitment mechanism employed by the17, June 15, 2010 ª2010 Elsevier Inc. 531
